| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5cfe28e4d3bd65805e35f09396c85821
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_765e5292fcbc398a203d74a81db5a966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a8d4cc16357235942e34e3fda3ffb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef0402ff2ff2eec7d8efe81ef156e14c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89dfd1e1e98d3de5d9ace2385b496b06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ceba070752048340ff9a5b6d9aadd3d |
| publicationDate |
2022-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11254724-B2 |
| titleOfInvention |
Glucagon derivatives |
| abstract |
The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity. |
| priorityDate |
2014-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |